The exact physiological function of amyloid-b precursor protein (APP) in endothelial cells is unknown. Endotheliumspecific APP-deficient (eAPP À/À ) mice were created to gain new insights into the role of APP in the control of vascular endothelial function. Endothelium-dependent relaxations to acetylcholine were significantly impaired in basilar arteries of global APP knockout (APP À/À ) and eAPP À/À mice (P < 0.05). In contrast, endothelium-independent relaxations to nitric oxide (NO)-donor diethylamine-NONOate were unchanged. Western blot analysis revealed that protein expression of endothelial nitric oxide synthase (eNOS) was significantly downregulated in large cerebral arteries of APP À/À mice and eAPP À/À mice as compared to respective wild-type littermates (P < 0.05). Furthermore, basal levels of cyclic guanosine monophosphate (cGMP) were also significantly reduced in large cerebral arteries of APP-deficient mice (P < 0.05). In contrast, protein expression of prostacyclin synthase as well as levels of cyclic adenosine monophosphate (cAMP) was not affected by genetic inactivation of APP in endothelial cells. By using siRNA to knockdown APP in cultured human brain microvascular endothelial cells we also found a significant downregulation of eNOS mRNA and protein expressions in APP-deficient endothelium (P < 0.05). These findings indicate that under physiological conditions, expression of APP in cerebral vascular endothelium plays an important protective function by maintaining constitutive expression of eNOS.
Background
Large cerebral arteries contribute significantly to the cerebral vascular resistance thereby participating in the regulation of cerebral blood flow. 1 Under physiological conditions, nitric oxide (NO) is continuously produced in endothelial cells by endothelial nitric oxide synthase (eNOS). 2 In the brain, basal production of endothelial NO is essential vascular protective mechanism responsible for maintenance of normal cerebrovascular function. [3] [4] [5] [6] Endothelial dysfunction is characterized by a loss of biologically active NO produced in the endothelium and is one of the most important events in initiation and progression of cerebrovascular disease. 7, 8 The amyloid-b precursor protein (APP) is an integral membrane protein expressed abundantly in the endothelium of large cerebral blood vessels as well as brain microvessels. [9] [10] [11] [12] [13] There are three isoforms of APPs, namely, APP 695 , APP 751 , and APP 770 , generated by alternative splicing of exons 7 and 8. APP 695 , predominantly expressed in neurons, is lacking two exons, Kunitz-type serine protease inhibitor (KPI) domain encoded by exon 7, and immunoregulatory OX-2 antigen domain (OX2) encoded by exon 8. APP 751 and APP 770 possess KPI domain while APP 770 contains an additional OX2 domain. 11, 14 Both APP 751 and APP 770 are expressed in endothelial cells. According to amyloid-b hypothesis, APP plays a central role in the pathogenesis of Alzheimer's disease. 15 Dysregulation of amyloidogenic APP processing results in the generation of amyloid-b (Ab) peptides responsible for development of amyloid plaques. Physiological role of APP in neuronal as well as in endothelial cells is incompletely understood. [16] [17] [18] In the present study, we tested the hypothesis that APP plays an important role in control of endothelial function of cerebral arteries. To advance this hypothesis, we performed studies on cerebral blood vessels derived from global APP knockout (APP À/À ) mice as well as in mice lacking APP only in the endothelium (eAPP flox/ flox ) mice were generated in our laboratory and were identified by PCR using previously described primers. 19 The female floxed offspring were crossed with male mice expressing Cre recombinase driven by the Tie2 promoter (Tie2-Cre; stock #004128, The Jackson Laboratory) to generate APP flox/þ ;Tie2-Cre À and APP flox/þ ;Tie2-Cre þ mice. The latter were used to breed with female APP flox/flox mice to generate APP flox/flox ;Tie2-Cre À (control littermates) mice and APP flox/flox ;Tie2-Cre þ (eAPP À/À ) mice, and the genotyping was performed by using Cre and floxed APP primers (Figure 1(a) ). In order to confirm endothelium-specific deletion of APP, mRNA was isolated from endothelial cells of mouse aorta for cDNA synthesis as described. 20 A PCR analysis using primers spanning the deletion site (exon 3) in the APP gene (Genbank accession NM_001198823.1): forward: 5 0 -GCAGATCACAAACGTGGTGG-3 0 and reverse: 5 0 -AGGAACTTGCACTTGTCGGG-3 0 was performed ( Figure 1(b) ). The following PCR conditions were used: 94 C for 30 s, 55 C for 30 s, and 72 C for 1 min (30 cycles). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primer forward: 5 0 -TGCCAAGGCTGTGGGCAAGG-3 0 and reverse: 5 0 -TGGGCCCTCAGATGCCTGCT-3 0 was used as reference controls (Figure 1(b) ). 20 In addition, quantitative real-time (qRT)-PCR (CFX Connect, BioRad, Hercules, CA, USA) was performed to evaluate APP expression in large cerebral arteries with and without endothelium. Briefly, endothelial cells were mechanically removed by gently rubbing of internal lumen (of isolated large cerebral arteries from eAPP À/À mice and wild-type littermates) over a stainless steel wire with diameter of 0.005 00 as previously described. 21, 22 ;Tie2-Cre þ ) mice. Endothelial cells (ECs) were isolated from mouse aortas and subjected to PCR analysis. The remaining aortas without endothelium were also analyzed. Please note that the PCR product was 168 bp for the exon 3-deleted APP allele and it was absent in eAPP À/À mice ECs. GAPDH was used as a loading control (168 bp).
arteries was cannulated with glass micropipette and was flushed with phosphate buffered saline (Gibco, Thermo Fisher, Waltham, MA, USA) to remove remaining endothelial cells. The methods for isolation of total RNA and reverse transcription-PCR as well as primers for qRT-PCR were same as described above. The obtained mRNAs were analyzed with qRT-PCR using universal SYBR green supermix (BioRad) under the following conditions: denaturalization at 95 C for 15 s and annealing at 58 C for 30 s. Copy numbers of the target gene were expressed as 2 ÀÁCT (where ÁC T ¼ C T of targeted gene (APP) À C T of internal control gene (GAPDH), and C T represents the threshold cycle). 23 All mice were maintained on standard chow with free access to drinking water. Sixteen-to 24-week-old male mice were anaesthetized with overdose of pentobarbital (200-250 mg/kg BW, i.p.) followed by exsanguination via cardiac puncture for blood collection. Investigations were not blinded regarding groups of animals studied (wild-type versus knockout mice). The brains were removed and placed in cold ( 
Systolic blood pressure
Systolic blood pressure was recorded in non-anesthetized mice by a tail-cuff method (Harvard Apparatus Ltd., Kent, UK) as described previously. 24 
Blood cell count
Blood cell count was performed in whole blood using VetScan Õ HM5 Hematology System (Abaxis, Union City, CA, USA). 25 Plasma levels of A , sAPP, and sAPP Blood samples were transferred to a tube containing EDTA, centrifuged at 2000 r/min (10 min, 4 C), and stored at À80 C until assayed. Mouse-specific Ab 1-40 ELISA kit (Invitrogen, Camarillo, CA, USA) as well as highly sensitive mouse/rat-specific sAPPa ELISA and mouse-specific sAPPb ELISA kits (IBL America, Minneapolis, MN, USA) were used to perform the measurements of circulating levels of Ab , sAPPa, and sAPPb, respectively. 26 Vascular reactivity studies in isolated basilar arteries Basilar artery was dissected free from surrounding tissues in cold Krebs solution under a microscope (Leica Wild M3C) and was transferred to small vessel chamber filled with Krebs solution. Vascular reactivity was studied in-vitro under pressurized conditions using a video dimension analyzer system (Living Systems Instrumentation, Burlington, VT, USA) as described elsewhere. 25, 27 Endothelium-dependent relaxations to acetylcholine (10 À9 to 10 À5 mol/L; Sigma, St. Louis, MO, USA) and endothelium-independent relaxations to the NO donor diethylammonium 10 
Western blot studies
Large cerebral arteries and hBMECs were homogenized in lysis buffer [composition (in mmol/L) 50 NaCl, 50 NaF, 50 sodium pyrophosphate, 5 EDTA, 5 EGTA, 0.1 Na 3 VO 4 , 10 HEPES, 0.5 PMSF, and 10 mg/ mL leupeptin, and 1% Triton X-100, pH 7.4] and stored at À80 C until assayed. 26 Equal amount of protein (15 mg) were separated using SDS-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membrane. Primary antibodies against APP (Invitrogen), eNOS (BD Biosciences, San Jose, CA, USA), and prostaglandin I 2 (PGI 2 ) synthase (Cayman) were used. As a loading control, blots were rehybridized with b-actin (Sigma). Densitometry was carried out using Odyssey imaging system (Li-Cor Biosciences, Lincoln, NE, USA).
Quantitation of eNOS mRNA
Total RNA was extracted from hHBMECs using RNeasy Plus Mini kit (Qiagen, Redwood City, CA, USA), and a reverse transcription of RNA to cDNA was performed using SuperScript III First-Strand Synthesis System kit (Invitrogen) as described. 10 The amount of target cDNA was quantified (in triplicate for each sample) using PCR with human specific eNOS (forward: 5 0 -GAGATGCTGTTGAAGCG GAT-3 0 and reverse: 5 0 -GGTAACCAGCACATT TGGGA-3 0 and b-actin primers. 28 
Measurement of intracellular superoxide anions
Intracellular superoxide anion levels in large cerebral arteries were quantified using a HPLC-based fluorescence detection of the oxidative product 2-hydroxyethidium. 12, 24 In brief, large cerebral arteries were equilibrated for 15 min in Krebs-HEPES buffer at 37 C in CO 2 incubator after which they were incubated with 50 mM dihydroethidium (Molecular Probes, Eugene, OR, USA) for additional 15 min. The samples were then washed of dihydroethidium and incubated for additional 1 h in fresh Krebs-HEPES (20 mM) buffer at 37 C. The arteries were homogenized in 4 C cold methanol and centrifuged at 10,000 r/min. The supernatants were analyzed by HPLC/fluorescence (Beckman Coulter, Brea, CA, USA) in 37% acetonnitrile in 0.1% trifluoroacetic acid aqueous solution. Data were quantified using 2-hydroxyethidium standard from the reaction between dihydroethidium and Fremy's salt 29 and normalized against tissue protein levels.
Determination of cyclic nucleotides levels
Colorimetric ELISA kits (Cell Biolabs Inc., San Diego, CA, USA) were used for measurements of cyclic guanosine 3 0 ,5 0 -monophosphate (cGMP) and cyclic adenosine 3 0 ,5 0 -monophosphate (cAMP) concentrations. Large cerebral arteries were incubated for 120 min in GIBCO Õ minimal essential medium (containing 0.1% BSA, 100 U/mL penicillin and 100 mg/mL streptomycin; Thermo Fischer Scientific Inc., Waltham, MA, USA) in the presence of 100 mmol/L 3-isobutyl-1-methylxanthine in order to inhibit the degradation of cyclic nucleotides by phosphodiesterases. After incubation, the arteries were removed, quickly frozen in liquid N 2 , and stored at À80 C until assayed. The arteries were homogenized in lysis buffer provided by the kit and after centrifugation the supernatants were subjected to cGMP and cAMP measurements according to the manufacturer's instructions.
Calculations and statistical analyses
All results are expressed as means AE SD and ''n'' denotes the number of animals from which tissues were harvested. Efficacy (maximal relaxation expressed as % of increase in intraluminal diameter measured during contraction with U46619 or maximal contraction expressed as percentage of decrease in the basal diameter) as well as the potency of the drugs (expressed as negative logarithm of the concentration that caused half-maximal response [pEC 50 value] 30 ) was determined for each individual concentration-response curve by non-linear regression analysis. 31 An unpaired Student's t-test was used to compare APP À/À and eAPP À/À mice with their wild-type littermate control mice. In addition, two-way ANOVA was used for multiple comparisons where appropriate. The concentration-response curves of the different groups were compared by ANOVA for repeated measurements followed by Bonferroni's correction (StatView). For these analyses, the group-by-concentration interaction effect was used to assess whether the response to a given agent differed between groups. A value of P < 0.05 was considered statistically significant. Blood cell counts were performed as there are reported studies showing that loxP/Cre technology may also affect hematopoiesis. 33, 34 However, analysis of peripheral blood cell count indicated that the profile of blood cells was unaltered in eAPP À/À mice as well as in APP À/À mice as compared to their respective wild-type littermates (Table 1 ). An exception was cell number of platelets that was significantly reduced in APP À/À mice (P < 0.05 vs. wild-type littermates; Table 1 ).
Results

Characteristics of APP
We also examined the plasma levels of Ab 1-40 as well as alpha-and beta-secretase cleaved soluble APP (sAPPa and sAPPb, respectively). Levels of Ab and sAPPa were undetectable in plasma of APP À/À mice (Table 1) . However, circulating levels of sAPPa and sAPPb were significantly reduced in eAPP À/À mice (P < 0.05 as compared to wild-type littermates; Table 1 ). Circulating levels of Ab tended to decrease in eAPP À/À mice but they did not reach statistical significance (P ¼ 0.1779; Table 1 ).
Endothelial function
Endothelium-dependent relaxations to acetylcholine were significantly impaired in isolated basilar arteries of APP À/À mice compared to wild-type littermates (group-by-concentration interaction P < 0.05; Figure 2(a) ). Moreover, endothelium-specific deletion of APP reduced relaxations to acetylcholine in eAPP À/À mice compared to wild-type littermates (group-by-concentration interaction P < 0.05; Figure 2b ). Indeed, the efficacy of acetylcholine was significantly decreased in APP À/À (28 AE 15%; n ¼ 6) as well as in eAPP À/À (30 AE 13%; n ¼ 7) mice (P (Figure 2(c) and (d), respectively) .
Expressions of APP, eNOS, and PGI 2 synthase
Western Blot analyses confirmed that APP protein expression is absent in large cerebral arteries of APP À/À mice (Figure 3(a) ). qRT-PCR analysis revealed that expression of APP mRNA was significantly reduced in large cerebral arteries of eAPP À/À mice (P < 0.05 vs. wild-type littermates; Figure 3(b) ). Furthermore, removal of endothelium significantly reduced expression of APP in large cerebral arteries of wild-type littermates but did not affect APP expression in eAPP À/À mice (Figure 3(b) ). Moreover, there is no significant difference between wild-type littermates and eAPP À/À mice arteries without endothelium (Figure 3(b) ) suggesting that expression of APP is abolished in endothelium of eAPP À/À mice. Protein expression of APP is also reduced by 60% in large cerebral arteries of eAPP À/À mice (P < 0.05 vs. wild-type littermates; Figure 3(c) ).
Most importantly, protein expression of eNOS was significantly reduced in large cerebral arteries of APP À/À mice (P < 0.05 vs. wild-type littermates; Figure 3(a) ). Moreover, eNOS expression was significantly reduced in eAPP À/À mice (P < 0.05 vs. wild-type littermates; Figure 3(c) ). In contrast, protein expression of PGI 2 synthase was not affected in large cerebral arteries derived from both APP À/À and eAPP À/À mice (Figure 3(d) and (e), respectively).
Levels of cyclic nucleotides
Basal cGMP levels were significantly reduced in large cerebral arteries of APP À/À and eAPP À/À mice as compared to their respective wild-type littermates (P < 0.05; Figure 4 
Superoxide anion production
Levels of intracellular superoxide anion were not different between large cerebral arteries isolated from eAPP 
Cell culture studies of hBMECs
To confirm that downregulation of eNOS is caused by genetic inactivation of APP in endothelium rather than some systemic alterations in APP-deficient mice, we treated hBMECs with siRNA against APP for three days. Treatment of hBMECs with APP siRNA resulted in significant attenuation of eNOS mRNA expression in hBMECs (P < 0.05 vs. control siRNA, Figure 5(a) ). Moreover, Western blot analysis revealed that knockdown of APP decreased protein expression of eNOS in hBMECs (P < 0.05 vs. control siRNA, Figure 5(b) ).
Contractions to endothelin-1
Concentration-dependent contractions to endothelin-1 were significantly enhanced in basilar arteries of eAPP À/À mice compared to wild-type littermates (group-by-concentration interaction P < 0.05; Figure 6 ). Moreover, the efficacy of ET-1 responses was increased in eAPP À/À mice (51 AE 6%; n ¼ 7) as compared to their wild-type littermates (36 AE 8%; ; n ¼ 8 wild-type; groupby-concentration interaction P < 0.05) and eAPP À/À mice compared to wild-type littermates (b; n ¼ 7 eAPP
; n ¼ 8 wild-type; group-by-concentration interaction P < 0.05). In contrast, endothelium-independent relaxations to NO-donor DEA-NONOate were unaffected in APP 
Discussion
This is the first study to examine the effects of APP deficiency on vascular function in mice and in cultured cerebrovascular endothelial cells. We report several major new findings. First, endothelium-dependent relaxations to acetylcholine were impaired in basilar arteries of APP À/À and eAPP À/À mice while endothelium-independent relaxations to NO donor were unaltered. Second, eNOS protein expression and cGMP levels were significantly reduced in large cerebral arteries of APP À/À and eAPP À/À mice. Third, knockdown of the APP gene by siRNA led to downregulation of eNOS mRNA and protein in cultured hBMECs. Our results demonstrate that in cerebrovascular endothelium, APP regulates expression and function of eNOS thereby exerting vascular protective properties under physiological conditions. There are numerous lines of evidence demonstrating expression and processing of APP in aortic and brain endothelial cells. 9, 11, 17, 26, 35 Notably, endothelial cells of cerebral blood vessels express higher levels of APP protein as compared to peripheral endothelial cells. 11 However, functional relevance of this observation is unknown and remains to be determined. The non-amyloidogenic processing of APP is constitutive in endothelium, and cleavage fragments of APP produced and released by the endothelium are part of normal cellular metabolism. 36 Hence, the presence of sAPPa and sAPPb in circulation suggests that APP and its cleavage products might play a role in normal human physiology. 16, 37 In the present study, we found that endotheliumdependent relaxations to acetylcholine were impaired in basilar arteries derived from APP À/À mice while relaxations to DEANONOate were not affected. These findings suggest that loss of APP in the endothelium causes selective impairment of endothelial function. Indeed, reactivity of smooth muscle cells to NO is not impaired in arteries derived from APP À/À mice. Moreover, our studies showed that eNOS protein expression was significantly downregulated in large arteries of APP À/À mice thereby providing the most likely mechanism responsible for observed alterations in vasomotor function in APP À/À mice. In order to test the selectivity of APP effects on endothelial function, we generated eAPP À/À mice lacking APP exclusively in endothelial cells. Consistent with findings in APP À/À mice, eNOS protein expression is downregulated and endothelium-dependent relaxations to acetylcholine were significantly impaired in basilar arteries of eAPP À/À mice. In contrast, endothelium-independent relaxations to DEANONOate were unchanged. It is also important to note that APP as well as all enzymes required for APP processing are present in vascular smooth muscle cells. 38 However, our findings clearly indicate that the endothelium (rather than smooth muscle) is responsible for the impaired vasomotor function in APP À/À mice. Moreover, systolic blood pressure was unchanged in eAPP À/À mice demonstrating that endothelial dysfunction observed in eAPP À/À mice was not caused by chronic increase in arterial blood pressure.
Our in vivo observations were confirmed by in vitro experiments demonstrating that genetic silencing of APP expression by siRNA significantly reduced expression of eNOS mRNA and protein in hBMECs. The observations made in cultured endothelium, support the interpretation that endothelial APP-deficiency per se (rather than alteration of some systemic factors) is responsible for loss of eNOS and endothelial dysfunction. We further investigated whether increased vascular superoxide anion production may be responsible for reduced bioavailability of NO and impaired endothelium-dependent vasodilatation. 7 However, we did not detect any changes in superoxide anion levels in large cerebral arteries of eAPP À/À mice. In aggregate, these findings suggest that reduced expression of eNOS is the most likely explanation for the endothelial dysfunction observed in APP-deficient cerebral arteries. On the other hand, endothelial dysfunction was also observed in Tg2576 transgenic mice overexpressing of mutated human APP. 25, 39 However, upregulated eNOS expression and increased production of superoxide anion were detected in these mice thereby causing reduced bioavailability of tetrahydrobiopterin and eNOS uncoupling. 25, 39 Thus, in agreement with hypothesis of the present study, overexpression of APP increases expression of eNOS. Our studies showed that basal levels of cGMP, the second messenger of NO, were significantly reduced in APP À/À mice and in eAPP À/À mice. This is in line with the observations made in eNOS-deficient mice demonstrating that loss of endogenous NO production via eNOS in vascular endothelium is responsible for reduction in basal cGMP levels. 40 Furthermore, in agreement with our findings, exogenous NO administration by NO-donor induced comparable increase in cyclic GMP and vasodilatation in wild type mice and eNOS-deficient mice. Likewise, it is important to note that loss of endogenous NO and reduced basal concentration of cyclic GMP does not inhibit, but in some studies even enhances, vasodilator responses to NO-donors. 41, 42 We also demonstrated that protein expression of PGI 2 synthase as well as levels of cAMP were not altered in large cerebral arteries of APP À/À or eAPP À/À mice indicating that the metabolism of PGI 2 , which dilates vascular smooth muscle cells directly, is unaffected. These findings suggest that selective loss of eNOS/ cGMP signaling is present in APP-deficient cerebral arteries. However, one limitation of our study is that we did not test other vasodilators such as adenosine, which may relax vascular smooth muscle cells of large cerebral arteries independently of cAMP signaling. 43 Endothelin-1 is a potent vasoconstrictor and mitogen both in vitro and in vivo.
44 Interestingly, our study shows that contractions to endothelin-1 are significantly enhanced in isolated basilar arteries of eAPP À/À mice. Reduced expression of eNOS observed in cerebral arteries is the most likely explanation for enhancement of endothelin-1 induced contractions. Our findings are consistent with the results of previous studies showing that under physiological conditions, NO inhibits endothelin-1 production via a cGMP-dependent mechanism and reduces endothelin-1-induced vasoconstriction of vascular smooth muscle cells. [45] [46] [47] As blood-brain barrier prevents the influx of soluble forms of APP 770 and APP 751 from the circulation into the brain, their concentrations are markedly lower in cerebrospinal fluid as compared to their circulating levels indicating that circulating cleavage products of APP are mostly derived from peripheral sources of APP 770 and APP 751 including platelets and endothelial cells. 14, 48 Notably, circulating levels of sAPPa were reduced ($30%) in eAPP À/À mice demonstrating that endothelial cells synthetize and release sAPPa. We also detected a slight decrease in circulating sAPPb in eAPP À/À mice; however, the difference was much smaller as compared to sAPPa. Similarly, levels of Ab tended to decrease but observed difference did not reach statistical significance thereby reinforcing the concept that non-amyloidogenic processing of APP is major constitutively active pathway in APP metabolism in endothelium.
Platelets count was significantly decreased in APP À/À mice but not in eAPP À/À mice. The reason is unclear but this could be related to the adaptive mechanisms designed to prevent pro-thrombotic function of platelets during APP deficiency. It is well known that human platelets contain high levels of APP which are mainly cleaved by non-amyloidogenic APP processing upon stimulation. [49] [50] [51] Since release of soluble APP has been reported to inhibit platelet activation via negative feedback regulation, global loss of APP might increase the risk of platelet aggregation and thrombosis. 52, 53 Furthermore, several studies indicate that platelets can produce up to 90% of circulating Ab (mainly Ab 1-40 peptide). 54, 55 However, it is well established that generation of sAPPa in platelets is higher than Ab peptides. 55, 56 Since the circulating levels of Ab 1-40 were unaltered in eAPP À/À mice, but undetectable in APP À/À mice, an involvement of circulating Ab 1-40 in downregulation of eNOS expression could be excluded. Whether APP and/or other cleavage products of APP have direct or indirect effects on expression and function of eNOS remains to be determined. 17 Our findings may help to explain beneficial effects of APP in experimental models of cerebral ischemia. Indeed, APP À/À mice are vulnerable to hypoxic injury and mortality rate is significantly higher in APP À/À mice exposed to cerebral ischemia as compared to wildtype animals. 57 Conversely, overexpression of wild-type APP in neuronal tissue exerts neuroprotective effect during ischemic injury induced by middle cerebral artery occlusion. 58 Notably, prior studies demonstrated that APP maturation and endogenous APP processing were impaired during cellular aging 59 thereby suggesting that aging-induced loss of APP function might increase the susceptibility to ischemia. The exact relative contribution of APP expression in vascular endothelium to protective effect of APP against brain ischemia will have to be determined in the future studies.
In conclusion, the present in vivo and in vitro studies demonstrate that the loss of APP in vascular endothelium decreases expression and function of eNOS. Our observations provide entirely novel insights into the previously unrecognized vascular protective function of APP.
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